Matthäus Getlik

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

Jiajun Zhu, Morgan A. Sammons, Greg Donahue et al. · Nature · 2015 · 482 citations · Full text

Cancer Research, Chromatin, Chromatin Remodeling +10

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia

Florian Grebien, Masoud Vedadi, Matthäus Getlik et al. · Nature Chemical Biology · 2015 · 282 citations · Full text

Hematological Malignancy, Medicine, Pharmacology +4

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Martin L. Sos, Stefanie Fischer, Roland T. Ullrich et al. · Proceedings of the National Academy of Sciences · 2009 · 255 citations · Full text

Cancer Biology, Tumor Biology, Oncology +18

Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation

Martin L. Sos, Haridas B. Rode, Stefanie Heynck et al. · Cancer Research · 2010 · 218 citations · Full text

Irreversible Egfr Inhibitors, Engineering, Tumor Cells +20

Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors

Jeffrey R. Simard, Matthäus Getlik, Christian Grütter et al. · Journal of the American Chemical Society · 2009 · 146 citations